IMVT - Immunovant, Inc.
收市後：
| 前收市價 | 20.98 |
| 開市 | 21.10 |
| 買盤 | 0.00 x 900 |
| 賣出價 | 0.00 x 900 |
| 今日波幅 | 20.77 - 21.35 |
| 52 週波幅 | 3.14 - 24.18 |
| 成交量 | |
| 平均成交量 | 1,019,511 |
| 市值 | 2.744B |
| Beta 值 (5 年，每月) | 1.02 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.68 |
| 業績公佈日 | 2023年8月03日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 26.50 |
InvestorPlaceThe Quant Trading System Picking Stocks That Soar 300%
Editor’s note: “The Quant Trading System Picking Stocks That Soar 300%” was previously published in January 2023. It has since been updated to include the most relevant information available. The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly picking stocks that were soaring 100%, 200%, and even 300%-plus in a matter of months? InvestorPlace - St
BenzingaImmunovant Could Potentially Be An M&A Target, Writes Analyst
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30. The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn). Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies. Related:
Insider Monkey12 Best Small-Cap Healthcare Stocks To Buy Now
In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […]
BenzingaImmunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody that matches batoclimab's IgG lowering without affecting albumin and LDL. HC Wainwright says the addition of IMVT-1402 broadens the anti-FcRn franchise. The analyst maintains a Buy rating with a price target of $16. Roivant is leveraging data and learnings from batoclimab studies to accelerate IMVT-1402's develop
Insider MonkeyThese 10 Stocks are Getting Crushed on Monday
In this article, we will take a look at the 10 stocks getting crushed on Monday. If you want to see some more companies on the list, go directly to These 5 Stocks are Getting Crushed on Monday. U.S. stocks inched up before the opening bell today. However, the gains couldn’t continue for long. All […]
BenzingaImmunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year
View more earnings on IMVTSee more from BenzingaModerna's Updated COVID-19 Shot Boosts Omicron ProtectionThe Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial DataDon't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.